Table 1 Patient characteristics.*
Nadroparin (N = 769) | Placebo (N = 381) | |
|---|---|---|
Age (years) | ||
Mean ± SD | 62.1 ± 10.3 | 63.7 ± 9.2 |
Median (Min - Max) | 64.0 (27-83) | 65.0 (36-84) |
Sex | ||
Female | 51.6 (397) | 52.0 (198) |
Male | 48.4 (372) | 48.0 (183) |
Cancer Site | ||
Gastrointestinala | 35.4 (272) | 38.8 (148) |
Lung | 25.9 (199) | 21.0 (80) |
Breast | 14.3 (110) | 14.4 (55) |
Ovary | 12.5 (96) | 12.3 (47) |
Pancreas | 4.7 (36) | 4.5 (17) |
Head and Neck | 2.5 (19) | 4.5 (17) |
Other | 4.8 (37) | 4.5 (17) |
Disease Stage | ||
Advanced | 69.8 (537) | 72.2 (275) |
Metastatic | 30.2 (233) | 27.8 (106) |
Chemotherapy naïve | ||
Yes | 52.7 (405) | 55.9 (213) |
No | 47.3 (364) | 44.1 (168) |
Number of chemotherapy cycles | ||
Mean ± SD | 3.2 ± 1.4 | 3.4 ± 1.5 |
Median (Min - Max) | 4.0 (1-7) | 4.0 (1-13) |
Central venous catheter | ||
Yes | 41.9 (322) | 38.6 (147) |